A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study follows people who received KYV-101 in an earlier study. KYV-101 is a treatment made from a person's own immune cells, with changes to their genes. Researchers will check for side effects that appear later and learn how long these changed cells stay in the body.
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- You agree to join the follow-up study after learning about it.
- You received KYV-101 at least once through a vein in an earlier KYV-101 treatment study.
Who can't join
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: * Provided informed consent for the LTFU study * Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol Exclusion Criteria: * Not applicable
Study sites (1)
CO
- University of Colorado, Denver · Denver, CO 80045Study Coordinator · Study contactMore trials in Denver